Age reversal is the tech world’s holy grail — can AI make it reality?

A Survival God for the Age of Abundance,” Peter H. Diamandis and Steven Kotler explore what it means to be human in a world ...

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating ...

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies ...

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

Detailed price information for Mink Therapeutics Inc (INKT-Q) from The Globe and Mail including charting and trades.
Technology Networks

Reprogramming T Cells Could Combat Immunotherapy-Resistant Pancreatic Cancer

Researchers showed that an experimental therapy indirectly converted suppressive immune cells into tumor-fighting cells. This ...

Why we need to do more to ensure nature thrives in Yorkshire - Rachael Bice

It is a privilege to lead a charity dedicated entirely to wildlife protection and restoration, as Yorkshire Wildlife Trust ...